SEDIA BIOSCIENCES CORPORATION

SEDIA BIOSCIENCES CORPORATION specializes in the development and manufacturing of advanced biopharmaceutical products, with core expertise in cell culture processes, downstream purification, and aseptic fill-finish operations for therapeutic biologics. The company applies rigorous quality control protocols aligned with cGMP standards to support the production of monoclonal antibodies, recombinant proteins, and other complex biotherapeutics. Technical capabilities include process development, scale-up validation, and analytical characterization using HPLC, mass spectrometry, and bioassay methodologies. Their focus on precision manufacturing and process robustness positions them as a niche provider for early-phase clinical supply and specialized biologics production. Award history is not available to determine specific agency relationships or project types. Consequently, no patterns of engagement with federal departments or programs can be inferred from the provided data. The primary NAICS code 325413 corresponds to Pharmaceutical and Medicine Manufacturing, indicating that SEDIA operates within the biopharmaceutical production vertical, focusing on active pharmaceutical ingredient synthesis and finished dosage form manufacturing. The company’s market positioning centers on contract development and manufacturing services for biologics, serving clients requiring compliant, scalable production infrastructure without direct commercial sales. As a small business structured as a 2L entity, SEDIA BIOSCIENCES CORPORATION is privately held and headquartered in Beaverton, Oregon. The company holds no federal certifications such as 8(a), HUBZone, or WOSB. Its geographic footprint is limited to its Oregon facility, where it maintains a dedicated cGMP-compliant manufacturing suite. The business operates as a specialized contract manufacturer within the federal biopharmaceutical supply chain, supporting research-driven and clinical-stage programs through technical manufacturing excellence.